BioCentury
ARTICLE | Finance

May 24 Quick Takes: Duke Street Bio debuts to develop PARP inhibitors

Plus Alvotech’s Stelara biosimilar demonstrates bioequivalence and updates from uniQure, CSL, Alpine and more

May 25, 2022 1:22 AM UTC

London-based oncology company Duke Street Bio Ltd. emerged from stealth with a PARP1-selective inhibitor — a compound class whose lower toxicity relative to first-generation PARP inhibitors ...



Access this Article